Immunome Stock Alpha and Beta Analysis
| IMNM Stock | USD 13.47 1.94 16.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immunome. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immunome over a specified time horizon. Remember, high Immunome's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Immunome's market risk premium analysis include:
Beta 2.29 | Alpha (0.66) | Risk 4.31 | Sharpe Ratio (0.08) | Expected Return (0.34) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Immunome |
Immunome Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immunome market risk premium is the additional return an investor will receive from holding Immunome long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immunome. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immunome's performance over market.| α | -0.66 | β | 2.29 |
Immunome expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immunome's Buy-and-hold return. Our buy-and-hold chart shows how Immunome performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Immunome Market Price Analysis
Market price analysis indicators help investors to evaluate how Immunome stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immunome shares will generate the highest return on investment. By understating and applying Immunome stock market price indicators, traders can identify Immunome position entry and exit signals to maximize returns.
Immunome Return and Market Media
The median price of Immunome for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 12.97 with a coefficient of variation of 13.31. The daily time series for the period is distributed with a sample standard deviation of 1.73, arithmetic mean of 13.02, and mean deviation of 1.43. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology Congres... | 09/13/2024 |
2 | Disposition of 14380 shares by Max Rosett of Immunome at 16.01 subject to Rule 16b-3 | 09/19/2024 |
3 | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/08/2024 |
4 | Immunome Acquires Zentalis Pharmaceuticals Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceutic... | 10/30/2024 |
5 | Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference | 11/05/2024 |
6 | FMR LLCs Strategic Acquisition of Immunome Inc Shares | 11/13/2024 |
7 | Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc | 11/15/2024 |
8 | Acquisition by Clay Siegall of 33943 shares of Immunome at 9.7787 subject to Rule 16b-3 | 11/22/2024 |
9 | Insider Buying Robert Lechleider Acquires Shares of Immunome Inc | 11/25/2024 |
About Immunome Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Immunome or other stocks. Alpha measures the amount that position in Immunome has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 5.82 | 3.09 | 6.63 | 4.38 | Net Debt To EBITDA | 2.04 | 0.55 | 3.43 | 3.6 |
Immunome Upcoming Company Events
As portrayed in its financial statements, the presentation of Immunome's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunome's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immunome's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immunome. Please utilize our Beneish M Score to check the likelihood of Immunome's management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Immunome
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Immunome Backtesting, Immunome Valuation, Immunome Correlation, Immunome Hype Analysis, Immunome Volatility, Immunome History and analyze Immunome Performance. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Immunome technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.